Melatonin combats molecular terrorism at the mitochondrial level
Open Access
|Nov 2010References
- Abe T, Takngi N, Nagano M, Furuza M, Takeo S (2004). Altered Bad localization and interaction between Bad and Bcl-Xin the hippocampus after transient global ischemia.: 159-168.
- Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ (1997). Melatonin is protective against MPTP-induced striated and hippocampal lesions., PL23-PL29.
- Acuna-Castroviejo D, Escames G, Carozo A, Leon J, Khaldy H, Reiter RJ (2002). Melatonin, mitochondrial homeostasis and mitochondrial-related diseases.: 133-152.
- Acuna-Castroviejo D, Martin M, Macias M, Escames G, Leon J, Khaldy H, Reiter RJ (2001). Melatonin, mitochondria, and cellular bioenergetics.: 65-74.
- Acuna-Castroviejo D, Escames G, Lopez LC, Hitos AB, Leon J (2005). Melatonin and nitric oxide: two required antagonists for mitochondrial homeostasis.: 159-168.
- Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF (2004). Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin.: 869-871.
- Antolin I, Mayo JC, Sainz RM, de Brio ML, Herrera F, Martin V, Rodriguez C (2002). Protective effect of melatonin in a chronic experimental model of Parkinson's disease.: 163-172.
- Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002). Chaperone suppression of alpha-synuclein toxicity in amodel in Parkinson's disease.: 685-688.
- Barlow-Walden LR, Reiter RJ, Abe M (1995). Melatonin stimulates brain glutathione peroxidase activity.: 497-502.
- Baydas G, Gursu MF, Yilmaz S (2002). Daily rhythm of glutathione peroxidase activity, lipid peroxidation and glutathione levels in tissues of pinealectomized rats.: 195-198.
- Beal MF (1992). Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?: 119-130.
- Benitez-King G (2006). Melatonin as a cytoskeletal modulator: implications for cell physiology and disease.: 1-9.
- Blask DE, Dauchy RT, Sauer LA (2005). Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.: 179-188.
- Borlongan CV, Kautonzis TK, Freeman TB, Cahill DW, Sanberg PR (1995). Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.: 254-257.
- Brainard GC, Hanifin JP, Rollag MD, Greeson J, Byrne B, Glickman G, Gerner E, Sanford B (2001). Human melatonin regulation in not mediated by the three cone photopic visual system.: 433-436.
- Brandon M, Baldi P, Wallace DC (2006). Mitochondrial mutations in cancer.: 4647-4662.
- Bromme HJ, Morke W, Peschke D, Ebelt H, Peschke E (2000). Scavenging effect of melatonin on hydroxyl radicals generated by alloxan.: 201-208.
- Brown GC (1992). Control of respiration and ATP synthesis in mammalian mitochondria and cells.: 1-13.
- Brown GC, Borutaite V (2004). Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols.: 44-49.
- Bubenik GA, Pang SF (1997). Melatonin levels in the gastrointestinal tissues of fish, amphibians and a reptile.: 415-419.
- Cabrera J, Reiter RJ, Tan DX, Qi W, Sainz RM, Mayo JC, Garcia JJ, Kim SJ, El-Sokkary G (2000). Melatonin reduces oxidative neurotoxicity due to quinolinic acid: in vitro and in vivo findings.: 507-514.
- Cadenas E, Poderoso JJ, Antunes F, Boveris A, Lizasoain I, Moro MA, Knowles RG, Darley-Usmar V, Moncada S (1996). Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose.: 877-880.
- Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (2005). A review of the multiple actions of melatonin on the immune system.: 189-200.
- Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernandez-Montesinos R, Guerrero JM, Pozo D (2006). The modulatory role of melatonin on immune responsiveness.: 423-431.
- Cavallo A, Dolan LM (1996). 6-Hydroxymelatonin sulfate excretion in human puberty.: 225-260.
- Chen CJ, Gao YQ, Li XJ, Shen DH, Sun FY (2005). Melatonin protects against MPTP/MPP-induced mitochondrial DNA oxidative damageand in vitro.: 34-42.
- Chen ST, Chuang JI, Hong MH, Li EI (2002). Melatonin attenuates MPP-induced neurodegeneration and glutathione impairment in the nigro striatal dopaminergic pathway.: 262-269.
- Coles CJ, Edmondson DE, Singer TP (1979). Inactivation of succinate dehydrogenase by 3-nitropropionic acid.: 5161-5167.
- Coto-Montes A, Tomas-Zapico C, Escames G, Leon J, Rodriguez-Colunga MJ, Tolivia D, Acuna-Castroviejo D (2003). Specific binding of melatonin to purified cell nuclei from mammary gland of Swiss mice: day-night variations and effect of continuous light.: 297-301.
- Coulom H, Birman S (2004). Chronic exposure to rotenone models: sporadic Parkinson's disease in: 10993-10998.
- de Almeida EA, Martinez GR, Klitzke CK, de Medeiros MH, Di Mascio P (2003). Oxidation of melatonin by singlet molecular oxygen produces N-acetyl-N-formyl-5-methoxykynuramine.: 131-137.
- Di Mauro S, Schon EA (2003). Mitochondrial respiratory-chain diseases.: 2656-2668.
- Dubocovich ML, Markowska M (2005). Functional MT1 and MT2 melatonin receptors in mammals.: 101-110.
- El-Sokkary G, Kamel ES, Reiter RJ (2003). Prophylactic effect of melatonin in reducing lead-induced neurotoxicity in the rat.: 461-470.
- Escames G, Leon J, Lopez LC, Acuna-Castroviejo D (2004). Mechanisms in the NMDA receptor inhibition by melatonin in the rat brain striatum.: 925-929.
- Escames G, Lopez LC, Tapias V, Utrilla MP, Reiter RJ, Hitos AB, Leon J, Rodriguez MI, Acuna-Castroviejo D (2006). Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice.: 71-78.
- Feany MB, Bender WW (2000).model of Parkinson's disease.: 394-398.
- Fernandez-Checa JC, Kaplowski N (2005). Hepatic mitochondrial glutathione: transport and role in disease and toxicity.: 263-273.
- Friguls B, Petegnief V, Justica C, Pallas M, Planas AM (2002). Activation of ERK and Akt signaling in focal cerebral ischemia: modulation of TGF-alpha and involvement of NMDA receptor.: 443-456.
- Fukutomi J, Fukado A, Fukado F, Hara M, Terada A, Yoshida M (2006). Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species.: 254-257.
- Ghafourifar P, Cadenas E (2005). Mitochondrial nitric oxide synthase.: 190-195.
- Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cardaro S, Corona G, Trimarchi G, Barberi I (2001). Effects of melatonin treatment in septic newborns.: 756-760.
- Goldman BD (1999). The circadian timing system and reproduction in mammals.: 679-685.
- Guenther AL, Schmidt SI, Laatsch H, Fotso S, Ness H, Ressmeyer AR, Poeggeler B, Hardeland R (2005). Reactions of the melatonin metabolite AMK (N-acetyl-5-methoxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetoamidomethyl-6-methoxycinnolinone and 3-nitro-AMK.: 251-260.
- Guerrero JM, Reiter RJ (2002). Melatonin-immune system relationships.: 167-179.
- Hardeland R (2005). Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance.: 119-130.
- Hardeland R and Poeggeler B (2003). Non-vertebrate melatonin.: 233-241.
- Hardeland R, Balzer I, Poeggeler B, Fuhrberg B, Uria H, Behrmann G, Wolf R, Meyer TJ, Reiter RJ (1995). On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photoxidation, and scavenging of free radicals.: 104-111.
- Hardeland R, Coto-Montes A, Poeggeler B (2003a). Circadian rhythms, oxidative stress and antioxidative defense mechanisms.: 921-962.
- Hardeland R, Poeggeler B, Niebergall R, Zelosko V (2003b). Oxidation of melatonin by carbonate radicals and chemiluminescence emitted during pyrrole ring cleavage.: 69-74.
- Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T, Reiter RJ (1995). Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates.: 627-634.
- Hirata F, Hayaishi O, Tokuyama T, Seno S (1974). In vitro and in vivo formation of two new metabolites of melatonin.: 1311-1313.
- Ishido M (2007). Melatonin inhibits maneb-induced aggregation of α-synclein in rat pheochromocytoma cells.: 125-130.
- Itoh MT, Takahashi N, Abe M, Shimiza K (2007). Expression and cellular localization of melatonin-synthesizing enzymes in the rat lens.: 92-96.
- Jan JE, Wasdell MB, Freeman RD, Bax M (2007). Evidence supporting the use of melatonin in short gestation infants.: 22-26.
- Jaworek J, Brzozowski T, Konturek SJ (2005). Melatonin as an organoprotector in the stomach and the pancreas.: 73-83.
- Jimenez-Jorge GM, Guerrero AJ, Jimenez-Caliam MC, Naranjo PJ, Lardone A, Carrillo-Vico C, Osuna C, Molinero P (2007). Evidence for melatonin synthesis in the rat brain during development.: 240-246.
- Jin BK, Shin DJ, Jeong MY, Gwag MR, Baik HW, Yoon KS, Cho YH, Joo WS, Kim YS, Baik HH (1998). Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenyl pyridinum.: 61-64.
- Jou MJ, Jou SB, Chen HM, Lin CH, Peng TI (2002). Critical role of mitochondrial reactive oxygen species formation in visible laser irradiation-induced apoptosis in rat brain astrocytes (RBA-1).: 507-516.
- Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST (2004). Visualization of the antioxidant effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes.: 55-70.
- Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, Wu HY, Chen CC, Hsu LF (2007). Melatonin protects against common deletion of mitochondrial DNA-augmented oxidative stress and apoptosis.: 389-403.
- Khaldy H, Escames G, Leon J, Bikjdaouene L, Acuna-Castroviejo D (2003). Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DNA depletion.: 491-500.
- Kilic U, Kilic E, Reiter RJ, Bassetti CL, Herman DM (2005a). Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice.: 67-71.
- Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM (2005b). Tissue-plasminogen activator-induced brain injury is reversed by melatonin: role of iNOS and Akt.: 151-155.
- Kolar J, Machackova I (2005). Melatonin in higher plants: occurrence and possible functions.: 333-341.
- Laakso ML, Porkka-Heiskanen T, Alila A, Steinberg D, Johansson G (1990). Correlation between salivary and serum melatonin: dependence on serum melatonin levels.: 39-50.
- Leon J, Acuna-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ (2004). Melatonin and mitochondrial function.: 765-790.
- Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ (2005). Melatonin mitigates mitochondrial malfunction.: 1-9.
- Leon J, Escames G, Rodriguez MI, Lopez LC, Tapias V, Entrena A, Camacho E, Carrion MD, Gallo MA, Espinosa A, Tan DX, Reiter RJ, Acuna-Castroviejo D (2006). Inhibition of neuronal nitric oxide synthase activity by N-acetyl-5-methoxykynuramine, a brain metabolite of melatonin.: 2023-2033.
- Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR, Pozo D (2003). Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro.: 204-211.
- Li XJ, Gu J, Lu SD, Sun FJ (2002). Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical.: 42-52.
- Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991). 3-Nitropropionic acid - exogenous animal neurotoxin and possible human striatal toxin.: 494-498.
- Ma X, Idle JR, Krausz KW, Tan DX, Ceraulo L, Gonzalez FJ (2006). Urinary metabolites and antioxidant products of exogenous melatonin in the mouse.: 343-349.
- Maldonado MD, Murrillo-Cabezas F, Terron MP, Flores LJ, Tan DX, Manchester LC, Reiter RJ (2007). The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma.: 1-11.
- Manda K, Ueno M, Anzai K (2007). AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice.: 386-393.
- Martin M, Macias M, Escames G, Leon J, Acuna-Castroviejo D (2000). Melatonin but not vitamins C and E maintains glutathione homeostasis in tert-butyl hydroperoxide induced mitochondrial oxidative stress.: 1677-1679.
- Matsura T, Nishida T, Togawa A, Horie S, Kusumoto C, Chata S, Nakada J, Ishibe Y, Yamada K, Ohta Y (2006). Mechanisms of protection by melatonin against acetaminophen-induced liver injury in mice.: 211-219.
- Matuszek Z, Reszka K, Chignell CF (1997). Reaction of melatonin and related indoles with hydroxyl radicals: ESR and spin trapping investigations.: 367-372.
- McIntyre IM, Norman TR, Burrows GD, Armstrong SM (1989). Human melatonin response to light is intensity dependent.: 149-156.
- Morgan IG, Boelen MK (1996). A retinal dark-light switch: a review of the evidence.: 399-409.
- Nam E, Lee SM, Koh SE, Joo WS, Maeng S, Im HI, Kim YS (2005). Melatonin protects against neuronal damage induced by 3-nitropropanic acid in rat striatum.: 90-96.
- Ortiz GG, Crespo-Lopez ME, Moran-Moguel C, Garcia JJ, Reiter RJ, Acuna-Castroviejo D (2001). Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis: 101-108.
- Pablos MI, Agapito MT, Gutierrez R (1995). Melatonin stimulates the activity of detoxifying enzyme glutathione peroxidase in several tissues of chicks.: 111-115.
- Pablos MI, Reiter RJ, Ortiz GG (1998). Rhythms of glutathione peroxidase and glutathione reductase in brain of chicks and their inhibition by light.: 69-75.
- Panda S, Nayak SK, Campo B, Walker JR, Hogenesch JB, Jegla T (2005). Illumination of melanopsin's signaling pathway.: 600-604.
- Pappolla MA, Reiter RJ, Bryant-Thomas TK, Poeggeler B (2003). Oxidative mediated neurodegeneration in Alzheimer's disease: melatonin and related antioxidants as neuroprotective agents.: 233-243.
- Peyrot F, Martin MT, Miguel J, Ducrocq C (2002). Reactivity of peroxynitrite with melatonin as a function of pH and COcontent.: 1-10.
- Pozo D, Reiter RJ, Calvo JR, Guerrero JM (1997). Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin.: 430-442.
- Pozo D, Garcia-Maurino S, Guerrero JM, Calvo RJ (2003). mRNA expression of nuclear receptor RZR/RORα, melatonin membrane receptor MT1, and hydroxyindole-O-methyltransferase in different populations of immune cells.: 48-54.
- Qi W, Reiter RJ, Tan DX, Garcia JJ, Manchester LC, Karbownik M, Calvo JR (2000). Chromium (III)-induced 8-hydroxydeoxyguanosine in DNA and its reduction by antioxidants: comparative effects of melatonin, ascorbate and vitamin E.: 2399-2402.
- Qi W, Reiter RJ, Tan DX, Manchester LL, Siu AW, Garcia JJ (2002). Increased levels of oxidatively damaged DNA induced by chromium (III) and HO: protection by melatonin and related molecules.: 54-61.
- Quay WB (1974). Pineal Chemistry in Cellular and Physiological Mechanisms. Springfield: Charles C. Thomas.
- Reiter RJ (1980). The pineal and its hormones in the control of reproduction in mammals.: 109-131.
- Reiter RJ (1987). The melatonin message: duration versus coincidence hypotheses.: 2119-2131.
- Reiter RJ (1991a). Melatonin: cell biology of its synthesis and of its physiological interactions.: 151-180.
- Reiter RJ (1991b). Melatonin: the chemical expression of darkness.: C153-C158.
- Reiter RJ (1995). Oxidative processes and antioxidative defense mechanisms in the aging brain.: 526-533.
- Reiter RJ, Richardson BA, Johnson LY, Ferguson BN, Dinh DT (1980). Pineal melatonin rhythm: reduction in aging Syrian hamsters.: 1372-1373.
- Reiter RJ, Craft CM, Johnson JE, King Jr. TS, Richardson BA, Vaughan GM, Vaughan MK (1981). Age-associated reduction in nocturnal pineal melatonin levels in female rats.: 1295-1297.
- Reiter RJ, Tan DX, Osuna C, Gitto E (2000). Actions of melatonin in the reduction of oxidative stress: a review.: 444-458.
- Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E (2005). When melatonin gets on your nerves: its beneficial effects in experimental models of stroke.: 104-17.
- Reiter RJ, Tan DX, Manchester LC, Simopoulos AP, Maldonado MD, Flores LJ, Terron MP (2007). Melatonin in edible plants (phytomelatonin): identification, concentrations, bioavailability and proposed functions.: 211-230.
- Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ (2004). Regulation of antioxidant enzymes: a significant role for melatonin.: 1-9.
- Rosen J, Than NN, Koch D, Poeggeler B, Laatsch H, Hardeland R (2006). Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C-substitued 3-indolinones.: 374-381.
- Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM (1986). Human melatonin production decreases with age.: 379-388.
- Sanchez-Barcello EJ, Cos S, Mediavilla D, Martinez-Compa C, Gonzalez A, Alonso-Gonzalez C (2005). Melatonin-estrogen interactions in breast cancer.: 217-222.
- Saravanan KS, Sindhu KM, Mohanakumar KP (2005). Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.: 157-155.
- Saravanan KS, Sindhu KM, Mohanakumar KP (2007). Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.: 247-253.
- Saravanan KS, Sindhu KM, Senthikumar KS, Mohanakumar KP (2006). L-Dephenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.: 28-40.
- Sawicka A, Reiter RJ, Tan DX, Wojtasievoicz K, Leneniewska A, Mavrin JK, Balachut D, Czarnocki Z (2004). The synthesis and the structure elucidation of N, O-diacetyl erivative of cyclic 3-hydroxymelatonin.: 425-433.
- Scheffler IE (1999). Mitochondria. New York: Wiley-Liss.
- Sever G, Atasoy BM, Ersoy Y, Arbak S, Sengoz M, Yegen BC (2004). Melatonin protects against ionizing radiation-induced oxidative damage to corpus cavernosum and urinary bladder in rats.: 241-246.
- Silva SO, Rodriguez MR, Carvalho SR, Catalani LA, Campa A, Ximenes VF (2004). Oxidation of melatonin and its catabolites, N-acetyl-N-formyl-5-methoxykynuramine and N-acetyl-5-methoxykynuramine, by activated leukocytes.: 171-175.
- Siu AW, Maldonado MD, Sanchez-Hidalgo M, Tan DX, Reiter RJ (2006). Protective effects of melatonin in experimental free radical-related ocular diseases.: 101-109.
- Skinner DC, Malpaux B (1999). High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus.: 4399-4405.
- Slominski A, Wortsman J, Tobin DJ (2005). The cutaneous serotoninergic/melatoninergic system: securing a place under the sun.: 176-194.
- Sofic E, Rimpapa Z, Jundorovic Z, Sapcanin A, Tahiorovic I, Rustembegovic A, Cao G (2005). Antioxidant capacity of neurohormone melatonin.: 349-358.
- Sousa SC, Castillo RF (2005). Protective effect of melatonin on rotenone plus Ca-induced mitochondrial oxidative stress and PC12 cell death.: 1110-1116.
- Stasica P, Ulanski P, Rosiak JM (1998). Melatonin as a hydroxyl radical scavenger.: 65-66.
- Stefulj J, Hortner M, Shosh M, Schavenstein K, Rinner I, Wolfler A, Semmler J, Liebmann PM (2001). Gene expression of key enzymes of melatonin synthesis of extrapineal tissues of the rat.: 243-247.
- Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ (1993). Melatonin: a potent, endogenous hydroxyl radical scavenger.: 57-60.
- Tan DX, Manchester LC, Reiter JR, Plummer BF, Hardes LJ, Weintraub ST, Vijayalaxmi, Shepherd AM (1998). A novel melatonin metabolite, cyclic 3-hydroxymelatonin, a biomarker of in vivo hydroxyl radical generation.: 614-620.
- Tan DX, Manchester CC, Reiter RJ, Qi WB, Zhang M, Weintraub ST, Cabrera J, Sainz RM, Mayo JC (1999a). Identification of highly elevated levels of melatonin in bone marrow: its origin and significance.: 206-214.
- Tan DX, Manchester LC, Reiter RJ, Plummer BF (1999b). Cyclic 3-hydroxymelatonin: a melatonin metabolite generated as a result of hydroxyl radical scavenging.: 70-74.
- Tan DX, Manchester LC, Reiter RJ, Plummer BF, Limson J, Weintraub ST, Qi W (2000). Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation.: 1177-1185.
- Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R (2002). Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger.: 181-182.
- Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, Reiter RJ (2003). Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin.: 75-78.
- Tan DX, Manchester LC, Di Mascio P, Martinez CR, Prado FM, Reiter RJ (2007a). Novel rhythms of N-acetyl-N-formyl-5-methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation.: 1724-1729.
- Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007b). One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and reactive-nitrogen species?: 28-42.
- Tatoyan A, Giulivi C (1998). Purification and characterization of nitric oxide synthase from rat liver mitochondria.: 11044-11048.
- Than NN, Heer C, Laatsch H, Hardeland R (2006). Reaction of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK) with the ABTS cation radical: identification of new oxidation products.: 15-24.
- Thomas B, Mohanokumar KP (2004). Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse nigrostriatum.: 25-32.
- Tomas-Zapico C, Coto-Montes A (2005). A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes.: 99-104.
- Tosini G (2000). Melatonin circadian rhythm in the retina of mammals.: 599-612.
- Tosini G, Chaurasia SS, Iuvone PM (2006). Regulation of arylakylamine-acetyltransferase (AANAT) in the retina.: 381-391.
- Tunez I, Montilla P, del Carmen Munoz M, Feijoo M, Salcedo M (2004). Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model in Huntington's disease.: 252-256.
- Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S, Honma K, Kondo T (1999). Melatonin induces gamma-glutamylcysteine synthase mediated by activator protein-1 in human vascular endothelial cells.: 838-847.
- Valko M, Morris H, Cronin MT (2005). Metals, toxicity and oxidative stress.: 1161-1208.
- Vijayalaxmi, Meltz ML, Reiter RJ, Herman TS (1999). Melatonin and protection from damage in blood and bone marrow: whole body radiation studies in mice.: 221-225.
- Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR Jr (2004). Melatonin as a radioprotective agent: a review.: 639-653.
- Winiarska K, Fraczyk T, Melinska D, Drozak J, Bryla J (2006). Melatonin attenuates diabetes-induced oxidative stress in rabbits.: 168-176.
- Witt-Enderby PA, Radio NM, Doctor JS, David VL (2006). Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.: 297-305.
- Xu J, Sun S, Wei W, Fu J, Qi W, Manchester LC, Tan DX, Reiter RJ (2007). Melatonin reduces mortality and oxidatively mediated hepatic and renal damage due to diquat treatment.: 166-171.
- Yamamoto H, Mohanan PV (2002). Melatonin attenuates brain mitochondria DNA damage induced by potassium cyanide in vivo and in vitro.: 29-36.
- Yamamoto H, Tang HW (1996). Preventive effect of melatonin against cyanide-induced seizures and lipid peroxidation in mice.: 89-92.
- Yamamoto H, Tang H (1998). Effects of 2-amino-7-phosphonohepatanoic acid, melatonin or NG-nitro-L-arginine on cyanide or N-methyl-D-aspartate induced neurotoxicity in rat cortical cells.: 13-18.
- Yoshimoto T, Uchino H, He QP, Li PA, Siesjo BK (2001). Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal cerebral ischemia in the rat.: 148-158.
- You JH, Carter LB, Reiter RJ, Jevtovic-Todorovic V (2006). Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brain.: 522-530.
- Zhang H, Squadrito GL, Uppa R, Pryor WA (1999). Reaction of peroxynitrite with melatonin: a mechanistic study.: 526-534.
- Zhou G, Kawata T, Furusawa Y, Aoki M, Hirayama R, Ando K, Ito H (2006). Protective effects of melatonin against low and high-LET irradiation.: 175-181.
- Zisapel N (2007). Sleep and sleep disturbances: biological basis and clinical implications.: 1174-1186.
Language: English
Page range: 137 - 149
Published on: Nov 1, 2010
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Related subjects:
© 2010 Russel Reiter, Sergio Paredes, Ahmet Korkmaz, Mei-Jie Jou, Dun-Xian Tan, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.